cholera
acut
diarrheal
infect
caus
ingest
toxigen
serogroup
bacterium
vibrio
cholera
global
burden
cholera
estim
million
case
death
annual
case
report
subsaharan
africa
recent
sinc
haiti
made
major
contribut
global
burden
although
cholera
prevent
control
measur
tradit
focus
cholera
treatment
improv
access
safe
water
sanit
hygien
wash
oral
cholera
vaccin
ocv
gain
promin
major
complementari
tool
comprehens
cholera
prevent
control
recommend
use
exist
ocv
preemptiv
choleraendem
set
target
highrisk
area
popul
reactiv
part
outbreak
respons
activ
june
establish
global
ocv
stockpil
initi
stock
million
dose
fund
multipl
partner
novemb
global
allianc
vaccin
immun
endors
fund
support
stockpil
march
total
ocv
campaign
conduct
countri
vaccin
global
stockpil
three
inactiv
wholecel
ocv
prequalifi
avail
global
use
dukor
kill
wholecel
monoval
cholera
vaccin
cholera
toxin
b
subunit
valneva
lyon
franc
shanchol
modifi
kill
bival
cholera
vaccin
shantha
biotechn
hyderabad
india
euvichol
modifi
kill
bival
cholera
vaccin
eubiolog
seoul
south
korea
two
vaccin
shanchol
euvichol
avail
global
stockpil
shanchol
euvichol
recommend
person
year
age
includ
pregnant
women
schedul
given
day
apart
ocv
safe
efficaci
effect
multipl
set
recent
singl
dose
shanchol
show
efficaci
sever
dehydr
cholera
short
term
month
major
implic
outbreak
control
cdc
conduct
sever
evalu
ocv
use
emerg
set
cdc
collabor
partner
includ
pan
american
health
organ
other
review
current
evid
ocv
use
emerg
set
conduct
realtim
model
estim
effect
use
limit
suppli
avail
ocv
dose
cholera
outbreak
haiti
earthquak
postemerg
period
haiti
cdc
conduct
addit
evalu
cholera
respons
inform
futur
vaccin
campaign
evalu
includ
ocv
coverag
survey
precampaign
postcampaign
knowledg
attitud
practic
kap
survey
postcampaign
kap
survey
show
increas
avail
soap
handwash
station
decreas
report
treatment
drink
water
highlight
need
comprehens
commun
messag
cholera
control
feasibl
ocv
campaign
cdc
support
thailand
ministri
public
health
implement
evalu
preemptiv
ocv
campaign
refuge
camp
coverag
precampaign
postcampaign
kap
survey
show
high
degre
accept
campaign
well
improv
wash
behavior
ocv
campaign
conduct
iraq
respons
cholera
outbreak
affect
person
live
select
refuge
camp
intern
displac
person
camp
collect
center
campaign
cdc
conduct
coverag
survey
collabor
iraq
ministri
health
overal
coverag
respond
report
receiv
cholera
prevent
messag
evalu
demonstr
feasibl
success
implement
ocv
vaccin
campaign
conflict
set
part
integr
approach
cholera
control
recent
million
dose
euvichol
releas
use
hurricaneaffect
depart
haiti
hurrican
matthew
octob
first
releas
euvichol
global
stockpil
approxim
person
commun
target
vaccin
singl
dose
largest
singledos
campaign
well
largest
emerg
stockpil
releas
date
cdc
part
haiti
ocv
taskforc
led
monitor
evalu
campaign
effort
includ
improv
laboratori
capac
stool
cultur
plan
coverag
survey
singledos
effect
studi
collabor
ministri
public
health
popul
partner
delay
evalu
conduct
howev
incountri
staff
train
field
survey
techniqu
laboratori
method
evalu
increas
capac
futur
evalu
activ
athough
ocv
campaign
clearli
demonstr
feasibl
emerg
choleraendem
set
addit
evalu
address
evid
gap
gap
includ
singledos
effect
effect
ocv
dose
halt
outbreak
reduc
diseas
burden
effect
second
dose
set
prolong
dose
interv
optim
integr
ocv
wash
shortterm
longerterm
cholera
control
emerg
choleraendem
set
singl
ocv
dose
might
particularli
use
emerg
set
might
enabl
vaccin
larger
popul
shorter
timefram
deliveri
challeng
typhoid
typhoid
fever
caus
bacterium
salmonella
enterica
serovar
typhi
respons
million
ill
death
global
year
true
cholera
typhoid
primarili
occur
southern
asia
subsaharan
africa
part
middl
east
latin
america
limit
access
safe
water
inadequ
sanit
infrastructur
poor
hygien
practic
often
result
rapid
urban
favor
transmiss
although
diseas
endem
factor
give
typhoid
high
epidem
potenti
outbreak
occur
period
includ
outbreak
caus
antimicrobi
strain
although
typhoid
prevent
control
effort
focus
primari
measur
wash
vaccin
major
complementari
strategi
recommend
use
exist
typhoid
vaccin
endem
diseas
control
outbreak
control
recent
howev
rapid
global
increas
antimicrobi
drug
resist
emphas
need
prompt
shortterm
prevent
control
effort
use
exist
newergener
typhoid
vaccin
two
typhoid
vaccin
avail
use
sever
countri
sinc
first
vaccin
singledos
inject
polysaccharid
vaccin
base
purifi
typhi
vi
antigen
vip
vaccin
use
person
year
age
second
vaccin
multidos
live
attenu
oral
vaccin
avail
capsul
formul
person
year
age
vaccin
safe
efficaci
effect
multipl
set
recent
avail
newergener
singledos
inject
typhoid
conjug
vaccin
tcv
sever
advantag
current
polysaccharid
vaccin
includ
higher
level
vaccin
effect
longer
durat
protect
ad
booster
respons
approv
use
children
year
age
detail
inform
variou
vaccin
avail
elsewher
despit
larg
bodi
evid
avail
current
typhoid
vaccin
vaccin
adopt
use
limit
global
cdc
work
partner
plan
monitor
evalu
emerg
use
typhoid
vaccin
categori
tropic
cyclon
fiji
ministri
health
fiji
conduct
emerg
typhoid
vaccin
campaign
vip
vaccin
target
cycloneaffect
area
part
postdisast
respons
small
proport
vaccin
also
use
area
affect
cyclon
experienc
typhoid
outbreak
period
cdc
conduct
impact
evalu
collabor
partner
show
reduct
diseas
burden
area
larg
proport
popul
vaccin
compar
unvaccin
area
protract
outbreak
kases
district
uganda
cdc
coordin
discuss
multipl
partner
includ
coalit
typhoid
uganda
ministri
health
expand
program
immun
sanofi
pasteur
lyon
franc
regard
vaccin
use
outbreak
control
cdc
investig
protract
natur
outbreak
conduct
costeffect
model
exercis
support
need
emerg
vaccin
howev
global
vaccin
shortag
caus
recal
certain
lot
sanofi
vip
vaccin
preclud
vaccin
use
cdc
work
india
stanford
univers
stanford
ca
usa
local
hospit
navi
mumbai
india
municip
corpor
local
govern
bodi
evalu
plan
introduct
tcv
public
sector
program
target
children
year
age
although
vaccin
introduct
occur
diseaseendem
set
evalu
find
includ
safeti
effect
accept
impact
provid
inform
futur
target
use
tcv
emerg
set
yellow
fever
viral
hemorrhag
fever
caus
yellow
fever
viru
genu
flaviviru
transmit
haemagogu
aed
spp
mosquito
yellow
fever
endem
tropic
region
countri
africa
south
central
america
case
death
africa
number
report
case
believ
greatli
underestim
challeng
surveil
diagnosi
yellow
fever
caus
sever
case
death
africa
current
yellow
fever
vaccin
live
attenu
vaccin
manufactur
substrain
strain
standard
dose
highli
efficaci
recipi
show
develop
protect
level
antibodi
lifelong
protect
mani
diseaseendem
countri
introduc
yellow
fever
vaccin
childhood
immun
schedul
sinc
late
without
prevent
mass
vaccin
campaign
age
near
time
introduct
howev
huge
gap
popul
immun
countri
introduc
yellow
fever
vaccin
coverag
routin
immun
program
mani
countri
suboptim
adult
countri
conduct
mass
prevent
campaign
unprotect
furthermor
recent
chang
environment
agricultur
condit
contribut
worldwid
resurg
ae
aegypti
mosquito
primari
vector
urban
set
larg
urban
outbreak
occur
infect
person
move
dens
popul
urban
set
popul
immun
low
ae
aegypti
mosquito
present
outbreak
respons
need
difficult
predict
global
stockpil
yellow
fever
vaccin
maintain
sinc
million
dose
distribut
stockpil
replenish
multipl
time
outbreak
respons
vaccin
angola
democrat
republ
congo
drc
led
use
almost
million
dose
vaccin
respons
largescal
campaign
target
million
person
kinshasa
capit
drc
august
time
howev
insuffici
vaccin
suppli
avail
global
fractionaldos
yellow
fever
vaccin
administ
subcutan
intramuscular
inject
evalu
small
control
studi
healthi
adult
use
mass
campaign
never
evalu
guidanc
drc
decid
administ
fraction
ml
dose
yellow
fever
vaccin
nonpregn
adult
children
year
age
pregnant
women
children
year
age
receiv
full
dose
evalu
whether
immunogen
respons
observ
person
vaccin
mass
campaign
suffici
confer
protect
yellow
fever
viru
cdc
partner
us
agenc
intern
develop
institut
national
de
recherch
biologiqu
kinshasa
nation
refer
laboratori
drc
conduct
cohort
studi
person
elig
vaccin
campaign
particip
provid
blood
sampl
day
vaccin
anoth
sampl
collect
year
vaccin
fraction
dose
found
induc
suffici
immun
respons
confer
protect
result
would
provid
support
evid
fractionaldos
yellow
fever
vaccin
strategi
control
outbreak
yellow
fever
evalu
drc
provid
immunogen
data
adult
children
year
age
howev
evalu
provid
immunogen
data
fractionaldos
vaccin
children
year
age
cdc
partner
uganda
viral
research
institut
entebb
uganda
infecti
diseas
institut
makerer
univers
kampala
uganda
conduct
random
control
trial
fractionaldos
yellow
fever
vaccin
children
month
age
trial
provid
immunogen
data
need
determin
whether
fractionaldos
vaccin
perform
similarli
full
dose
youngest
age
group
elig
yellow
fever
vaccin
ad
bodi
knowledg
use
fractionaldos
vaccin
outbreak
respons
human
infect
ebola
viru
caus
hemorrhag
fever
diseas
high
casefat
rate
sporad
outbreak
report
sinc
within
genu
ebolaviru
famili
filovirida
speci
known
caus
human
diseas
zair
ebolaviru
zebov
sudan
ebolaviru
ebolaviru
bundibugyo
ebolaviru
humantohuman
transmiss
occur
percutan
mucou
membran
contact
blood
bodi
fluid
infect
person
ebola
outbreak
west
africa
largest
filoviru
diseas
outbreak
record
caus
zebov
strain
month
outbreak
caus
suspect
case
death
guinea
liberia
sierra
leon
ebola
vaccin
deliveri
atrisk
popul
final
stage
outbreak
possibl
expedit
vaccin
develop
driven
graviti
public
health
emerg
outbreak
sever
clinic
trial
investig
expand
access
protocol
use
singledos
recombin
replicationcompet
vesicular
stomat
viru
vsv
vector
encod
zebov
glycoprotein
rvsvzebov
partner
conduct
clusterrandom
ring
vaccin
trial
guinea
show
efficaci
ci
random
cluster
atrisk
adult
ring
includ
contact
contact
contact
infect
person
advers
event
mild
selflimit
seriou
advers
event
fever
anaphylaxi
judg
relat
vaccin
casepati
recov
vaccin
offer
healthcar
worker
hcw
part
clinic
trial
part
expand
access
emerg
ring
vaccin
new
cluster
aros
countri
cdc
sierra
leon
trial
introduc
vaccin
ebola
strive
evalu
largest
safeti
sampl
vaccineassoci
advers
event
observ
nearli
particip
although
vaccin
yet
licens
avail
evid
support
efficaci
safeti
rvsvzebov
vaccin
ring
vaccin
thu
rapid
access
vaccin
atrisk
group
regard
public
health
commun
major
adjunct
measur
consider
futur
outbreak
respons
cdc
engag
assist
countri
incorpor
vaccin
deliveri
emerg
respons
plan
develop
guidelin
protocol
ebola
vaccin
respons
help
ensur
activ
standard
evidencebas
wellcoordin
overal
ebola
outbreak
respons
effort
avail
standard
protocol
approv
atrisk
countri
would
facilit
evalu
vaccin
respons
emerg
cdc
support
implement
research
need
inform
polici
decis
use
unlicens
ebola
vaccin
includ
addit
regulatori
approv
requir
need
set
expand
access
feasibl
vaccin
introduct
potenti
interact
ongo
immun
procedur
schedul
vaccin
accept
hesit
commun
strategi
ensur
adequ
cold
chain
capac
vaccin
storag
transport
field
site
also
need
evalu
rvsvzebov
vaccin
requir
storag
standard
capac
nation
immun
program
africa
stabil
data
manufactur
merck
co
kenilworth
nj
usa
suggest
singledos
vial
pfuml
stabl
day
merck
co
per
comm
would
improv
feasibl
use
standard
cold
chain
equip
implement
vaccin
remot
area
ring
vaccin
vaccin
strategi
ebola
avail
effect
data
support
use
addit
respons
strategi
includ
geograph
target
hcw
vaccin
research
need
explor
effect
strategi
use
futur
geograph
target
vaccin
may
appropri
area
transmiss
welldefin
dens
popul
vaccin
strategi
target
geograph
focus
hcw
also
like
feasibl
implement
quickli
fix
vaccin
site
would
requir
highqual
contact
trace
need
ring
vaccin
postvaccin
coverag
evalu
would
use
assess
success
vaccin
strategi
preemptiv
vaccin
hcw
highrisk
countri
strategi
might
prevent
anoth
largescal
outbreak
data
support
durat
effect
need
inform
time
revaccin
potenti
effect
licensur
rvsvzebov
vaccin
expect
addit
candid
vaccin
continu
studi
clinic
trial
prelicensur
period
plan
emerg
ring
vaccin
rvsvzebov
vaccin
take
account
new
evid
guidanc
support
use
altern
vaccin
candid
strategi
cdc
contribut
develop
preliminari
guidanc
implement
licens
ebola
vaccin
part
global
ebola
vaccin
implement
team
led
cdc
emerg
vaccin
implement
activ
enhanc
global
health
secur
enabl
rapid
contain
vpd
outbreak
sourc
activ
built
incountri
respons
capac
provid
valuabl
evid
inform
futur
emerg
vaccin
deliveri
countri
involv
global
countri
risk
vpd
outbreak
cdc
contribut
develop
updat
guidelin
countri
partner
use
respons
plan
effort
exampl
includ
updat
posit
paper
cholera
vaccin
expect
updat
posit
paper
typhoid
vaccin
expect
global
ebola
vaccin
implement
team
guidanc
document
ebola
vaccin
implement
plan
evalu
emerg
vaccin
present
distinct
challeng
predict
need
emerg
anticip
way
expand
vaccin
avail
critic
global
shortag
deliv
evalu
new
product
ebola
epidem
acceler
vaccin
clinic
trial
could
set
preced
rapid
clinic
develop
countermeasur
futur
infecti
diseas
outbreak
integr
vaccin
emerg
respons
vpd
outbreak
continu
augment
global
health
secur
reduc
diseas
burden
mortal
rate
vulner
popul
avert
pathogen
spread
across
intern
border
lesson
learn
emerg
vaccin
implement
might
inform
respons
new
vaccin
develop
pipelin
vaccin
middl
east
respiratori
syndrom
coronaviru
lassa
viru
marburg
viru
zika
viru
rapid
respons
would
also
requir
